We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Coya Therapeutics, Inc. (COYA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Coya Therapeutics, Inc. is a member of our Medical group, which includes 884 different companies and currently sits at #11 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Coya Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for COYA's full-year earnings has moved 17.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that COYA has returned about 4.7% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 1.8% on a year-to-date basis. This means that Coya Therapeutics, Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Quest Diagnostics (DGX - Free Report) . The stock is up 22.5% year-to-date.
Over the past three months, Quest Diagnostics' consensus EPS estimate for the current year has increased 1.1%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Coya Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 431 individual stocks and currently sits at #159 in the Zacks Industry Rank. Stocks in this group have gained about 6.4% so far this year, so COYA is slightly underperforming its industry this group in terms of year-to-date returns.
Quest Diagnostics, however, belongs to the Medical - Outpatient and Home Healthcare industry. Currently, this 14-stock industry is ranked #66. The industry has moved +14.8% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Coya Therapeutics, Inc. and Quest Diagnostics as they could maintain their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Coya Therapeutics, Inc. (COYA) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Coya Therapeutics, Inc. (COYA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Coya Therapeutics, Inc. is a member of our Medical group, which includes 884 different companies and currently sits at #11 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Coya Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for COYA's full-year earnings has moved 17.5% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that COYA has returned about 4.7% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 1.8% on a year-to-date basis. This means that Coya Therapeutics, Inc. is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Quest Diagnostics (DGX - Free Report) . The stock is up 22.5% year-to-date.
Over the past three months, Quest Diagnostics' consensus EPS estimate for the current year has increased 1.1%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Coya Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 431 individual stocks and currently sits at #159 in the Zacks Industry Rank. Stocks in this group have gained about 6.4% so far this year, so COYA is slightly underperforming its industry this group in terms of year-to-date returns.
Quest Diagnostics, however, belongs to the Medical - Outpatient and Home Healthcare industry. Currently, this 14-stock industry is ranked #66. The industry has moved +14.8% so far this year.
Going forward, investors interested in Medical stocks should continue to pay close attention to Coya Therapeutics, Inc. and Quest Diagnostics as they could maintain their solid performance.